{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:08:52Z","timestamp":1765807732740,"version":"3.37.3"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"12","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 DA036297","R01 DA125698"],"award-info":[{"award-number":["U01 DA036297","R01 DA125698"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007813","name":"Center for AIDS Research","doi-asserted-by":"publisher","award":["P30 AI094189"],"award-info":[{"award-number":["P30 AI094189"]}],"id":[{"id":"10.13039\/100007813","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,31]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>People who inject drugs (PWID) face disparities in human immunodeficiency virus (HIV) treatment outcomes and may be less likely to achieve durable viral suppression. We characterized transitions into and out of viral suppression from 1997 to 2017 in a long-standing community-based cohort study of PWID, the AIDS Link to Intravenous Experience (ALIVE) Study, analyzing HIV-positive participants who had made a study visit in or after 1997. We defined the probabilities of transitioning between 4 states: 1) suppressed, 2) detectable, 3) lost to follow-up, and 4) deceased. We used multinomial logistic regression analysis to examine factors associated with transition probabilities, with a focus on transitions from suppression to other states. Among 1,061 participants, the median age was 44 years, 32% were female, 93% were African-American, 59% had recently injected drugs, and 28% were virologically suppressed at baseline. Significant improvements in durable viral suppression were observed over time; however, death rates remained relatively stable. In adjusted analysis, injection drug use and homelessness were associated with increased virological rebound in earlier time periods, while only age and race were associated with virological rebound in 2012\u20132017. Opioid use was associated with an increased risk of death following suppression in 2012\u20132017. Despite significant improvements in durable viral suppression, subgroups of PWID may need additional efforts to maintain viral suppression and prevent premature mortality.<\/jats:p>","DOI":"10.1093\/aje\/kwz258","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T20:12:13Z","timestamp":1573503133000},"page":"2086-2096","source":"Crossref","is-referenced-by-count":11,"title":["Durable HIV Suppression Among People Who Inject Drugs From a Community-Based Cohort Study in Baltimore, Maryland, 1997\u20132017"],"prefix":"10.1093","volume":"188","author":[{"given":"Becky L","family":"Genberg","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory D","family":"Kirk","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland"},{"name":"Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquie","family":"Astemborski","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Lee","sequence":"first","affiliation":[{"name":"Food and Drug Administration, US Department of Health and Human Services, Silver Spring, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noya","family":"Galai","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenrad E","family":"Nelson","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Vlahov","sequence":"first","affiliation":[{"name":"Departments of Epidemiology and Public Health, School of Nursing, Yale University, Orange, Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D","family":"Celentano","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti H","family":"Mehta","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"volume-title":"Ending AIDS: Progress Towards the 90-90-90 Targets","year":"2017","author":"Joint United Nations Program on HIV\/AIDS","key":"2020022404093780000_ref1"},{"issue":"5","key":"2020022404093780000_ref2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.7326\/0003-4819-157-5-201209040-00005","article-title":"U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008","volume":"157","author":"Althoff","year":"2012","journal-title":"Ann Intern Med"},{"issue":"12","key":"2020022404093780000_ref3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"2020022404093780000_ref4","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/cid\/cit003","article-title":"Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001\u20132009","volume":"56","author":"Hanna","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2020022404093780000_ref5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/cid\/ciu834","article-title":"Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access","volume":"60","author":"Delaugerre","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2020022404093780000_ref6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/jama.2012.5927","article-title":"Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy","volume":"308","author":"Yehia","year":"2012","journal-title":"JAMA"},{"issue":"16","key":"2020022404093780000_ref7","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1097\/QAD.0b013e328363bff2","article-title":"Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users","volume":"27","author":"Westergaard","year":"2013","journal-title":"AIDS"},{"issue":"4","key":"2020022404093780000_ref8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/QAI.0b013e3182433288","article-title":"Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy","volume":"59","author":"Milloy","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"2020022404093780000_ref9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/QAI.0b013e3181f2ac87","article-title":"Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level","volume":"55","author":"Lima","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"2020022404093780000_ref10","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/cid\/cir526","article-title":"Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy","volume":"53","author":"Mugavero","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2020022404093780000_ref11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/aje\/kwp347","article-title":"Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden","volume":"171","author":"Cole","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"4","key":"2020022404093780000_ref12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10461-014-0927-4","article-title":"Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART)","volume":"19","author":"Viswanathan","year":"2015","journal-title":"AIDS Behav"},{"issue":"3","key":"2020022404093780000_ref13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/QAI.0b013e318258c696","article-title":"Establishment, retention, and loss to follow-up in outpatient HIV care","volume":"60","author":"Fleishman","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"2020022404093780000_ref14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/cid\/cir491","article-title":"Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy","volume":"53","author":"Westergaard","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2020022404093780000_ref15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11524-011-9562-9","article-title":"Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users","volume":"88","author":"Palepu","year":"2011","journal-title":"J Urban Heal"},{"issue":"6 suppl","key":"2020022404093780000_ref16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10461-007-9238-3","article-title":"Residential transience and HIV risk behaviors among injection drug users","volume":"11","author":"German","year":"2007","journal-title":"AIDS Behav"},{"issue":"7","key":"2020022404093780000_ref17","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/jech-2014-205079","article-title":"Socio-economic marginalization in the structural production of vulnerability to violence among people who use illicit drugs","volume":"69","author":"Richardson","year":"2015","journal-title":"J Epidemiol Community Health"},{"issue":"1","key":"2020022404093780000_ref18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3851\/IMP3265","article-title":"Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting","volume":"24","author":"Ladak","year":"2019","journal-title":"Antivir Ther"},{"issue":"5","key":"2020022404093780000_ref19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00126334-200304150-00009","article-title":"Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use","volume":"32","author":"Palepu","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"26","key":"2020022404093780000_ref20","first-page":"719","article-title":"Vital signs: demographic and substance use trends among heroin users\u2014United States, 2002\u20132013","volume":"64","author":"Jones","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2020022404093780000_ref21","doi-asserted-by":"crossref","DOI":"10.1186\/s12981-016-0108-9","article-title":"Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: an ethno-epidemiological study","volume":"13","author":"Small","year":"2016","journal-title":"AIDS Res Ther"},{"issue":"50-51","key":"2020022404093780000_ref22","first-page":"1378","article-title":"Increases in drug and opioid overdose deaths\u2014United States, 2000\u20132014","volume":"64","author":"Rudd","year":"2016","journal-title":"Am J Transplant"},{"issue":"7","key":"2020022404093780000_ref23","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamapsychiatry.2014.366","article-title":"The changing face of heroin use in the United States: a retrospective analysis of the past 50 years","volume":"71","author":"Cicero","year":"2014","journal-title":"JAMA Psychiat"},{"key":"2020022404093780000_ref24","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.addbeh.2016.08.033","article-title":"Prescription opioid use disorder and heroin use among 12\u201334 year-olds in the United States from 2002 to 2014","volume":"65","author":"Martins","year":"2017","journal-title":"Addict Behav"},{"issue":"1","key":"2020022404093780000_ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0376-8716(94)01082-V","article-title":"Using social network analysis to study patterns of drug use among urban drug users at high risk for HIV\/AIDS","volume":"38","author":"Latkin","year":"1995","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"2020022404093780000_ref26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213357","article-title":"Rising role of prescription drugs as a portal to injection drug use and associated mortality in Baltimore, Maryland","volume":"14","author":"Cepeda","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"2020022404093780000_ref27","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/002204269102100406","article-title":"The ALIVE Study: a longitudinal study of HIV-1 infection in intravenous drug users: description of methods","volume":"21","author":"Vlahov","year":"1991","journal-title":"J Drug Issues"},{"issue":"5","key":"2020022404093780000_ref28","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.socscimed.2004.12.024","article-title":"The social structural production of HIV risk among injecting drug users","volume":"61","author":"Rhodes","year":"2005","journal-title":"Soc Sci Med"},{"issue":"1","key":"2020022404093780000_ref29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/epirev\/mxh005","article-title":"The social epidemiology of human immunodeficiency virus\/acquired immunodeficiency syndrome","volume":"26","author":"Poundstone","year":"2004","journal-title":"Epidemiol Rev"},{"issue":"3","key":"2020022404093780000_ref30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/014662167700100306","article-title":"The CES-D Scale: a self-report depression scale for research in the general population","volume":"1","author":"Radloff","year":"1977","journal-title":"Appl Psychol Meas"},{"issue":"9","key":"2020022404093780000_ref31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2020022404093780000_ref32","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/M17-2242","article-title":"HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015","volume":"169","author":"Nance","year":"2018","journal-title":"Ann Intern Med"},{"issue":"13","key":"2020022404093780000_ref33","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1097\/QAD.0000000000001164","article-title":"Increased antiretroviral therapy prescription and HIV viral suppression among persons receiving clinical care for HIV infection","volume":"30","author":"Bradley","year":"2016","journal-title":"AIDS"},{"issue":"7","key":"2020022404093780000_ref34","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(17)30053-X","article-title":"Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study","volume":"4","author":"O\u2019Connor","year":"2017","journal-title":"Lancet HIV"},{"author":"Sun","key":"2020022404093780000_ref35"},{"issue":"7","key":"2020022404093780000_ref36","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/hiv.12603","article-title":"Monitoring the HIV continuum of care in key populations across Europe and Central Asia","volume":"19","author":"Brown","year":"2018","journal-title":"HIV Med"},{"key":"2020022404093780000_ref37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/1874613601610010127","article-title":"HIV infection care and viral suppression among people who inject drugs, 28 U.S. jurisdictions, 2012\u20132013","volume":"10","author":"Karch","year":"2016","journal-title":"Open AIDS J"},{"issue":"14","key":"2020022404093780000_ref38","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1097\/QAD.0000000000001183","article-title":"A longitudinal, HIV care continuum: 10-year restricted mean time in each care continuum stage after enrollment in care, by history of IDU","volume":"30","author":"Lesko","year":"2016","journal-title":"AIDS"},{"author":"Genberg","key":"2020022404093780000_ref39"},{"author":"Genberg","key":"2020022404093780000_ref40"},{"issue":"2","key":"2020022404093780000_ref41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/02791072.2017.1394508","article-title":"Sold as heroin: perceptions and use of an evolving drug in Baltimore, MD","volume":"50","author":"Mars","year":"2018","journal-title":"J Psychoactive Drugs"},{"issue":"5","key":"2020022404093780000_ref42","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/add.14474","article-title":"Illicit fentanyls in the opioid street market: desired or imposed?","volume":"114","author":"Mars","year":"2019","journal-title":"Addiction"},{"issue":"5","key":"2020022404093780000_ref43","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1089\/apc.2011.0196","article-title":"Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users","volume":"26","author":"Hadland","year":"2012","journal-title":"AIDS Patient Care STDS"},{"issue":"8","key":"2020022404093780000_ref44","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/QAD.0000000000001777","article-title":"Social and structural factors associated with greater time with a plasma HIV-1 RNA viral load above log10(1500) copies\/ml among illicit drug users","volume":"32","author":"Kennedy","year":"2018","journal-title":"AIDS"},{"issue":"8","key":"2020022404093780000_ref45","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/cid\/ciw416","article-title":"Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis","volume":"63","author":"Low","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2020022404093780000_ref46","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1521\/aeap.14.6.367.24075","article-title":"Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users","volume":"14","author":"Macalino","year":"2002","journal-title":"AIDS Educ Prev"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwz258\/30988884\/kwz258.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/aje\/article-pdf\/188\/12\/2086\/32614583\/kwz258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/aje\/article-pdf\/188\/12\/2086\/32614583\/kwz258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T20:47:35Z","timestamp":1612298855000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/188\/12\/2086\/5631854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,11,19]]},"published-print":{"date-parts":[[2019,12,31]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwz258","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"type":"print","value":"0002-9262"},{"type":"electronic","value":"1476-6256"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,11,19]]}}}